Pill Identifier App

Label Changes for:

Xalatan (latanoprost ophthalmic solution)

March 2012

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

March 2012

ADVERSE REACTIONS

  • periorbital and lid changes resulting in deepening of the eyelid sulcus
     

August 2010

ADVERSE REACTIONS

Clinical Practice
  • dizziness
  • headache
Hide
(web4)